基因重组人粒细胞集落刺激因子在骨肉瘤大剂量综合化疗中的临床应用研究

目的　研究基因重组人粒细胞集落刺激因子 (rhG CSF)对骨肉瘤大剂量综合化疗所致白细胞和抗中性粒细胞计数 (ANC)减少的防治作用及毒副反应。方法　将 5 8例患者按经济情况分为研究组及对照组 ,均采用相同的化疗方案 ,研究组于化疗后 72h给予皮下注射rhG CSF 15 0 μg ,连用 5～ 7d。对照组化疗后给予常规升白细胞药物。结果　rhG CSF可明显减轻化疗所致白细胞和ANC的下降程度 ,缩短白细胞和ANC降至正常值以下的持续时间 ,促进白细胞和ANC的早日恢复 ,降低化疗延迟率及延迟时间 ,提高化疗完成率。rhG CSF副作用较轻 ,且可以耐受。结论　rhG CSF可有效防治白细胞和ANC的减少 ,提高化疗完成率 ,是防止化疗所致骨髓抑制的有效方法

Clinical study on using recombinant human granulocyte colony stimulating factor(rhG-CSF) in high-dose combined chemotherapy of osteosarcoma

Objective The clinical usefulness of rhG CSF was evaluated in patients with leukopenia and neutropenia induced by high dose combined chemotherapy for osteosarcoma and rhG CSF′s side effects.Methods A series of 58 osteosarcoma patients were divided into study group and control group (according their economic situation) and were treated with same chemotherapy regimen.rhG CSF at a dose of 150 μg/body daily was given subcutaneously 72 h after the termination of chemotherapy for five to seven days in study group.While normal medicine was given in control group.Results rhG CSF significantly increased the total white cell count (WBC) and absolute neutrophil count (ANC) at nadir,and shortened the duration of leukopenia with WBC<4 0×10 9/L and ANC<2 5×10 9/L,reduced the number of recovery days to normal and increased the completeness rate of chemotherapy.The side effect of rhG CSF was mild and tolerable.Conclusion rhG CSF is effective against the decrease of WBC and ANC,is able to improve chemotherapy′s success rate;using rhG CSF is an effective remedy for preventing and treating the bone marrow arrest induced by chemotherapy.